Literature DB >> 2106927

Pneumocystis carinii pneumonia.

S Thomas1, M O'Doherty, N Bateman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106927      PMCID: PMC1662061          DOI: 10.1136/bmj.300.6719.211

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  22 in total

1.  Simple nebuliser modification to enhance alveolar deposition of pentamidine.

Authors:  A K Simonds; S P Newman; M A Johnson; N Talaee; C A Lee; S W Clarke
Journal:  Lancet       Date:  1989-10-21       Impact factor: 79.321

2.  Inhaled pentamidine and hypoglycemia.

Authors:  J A Karboski; P J Godley
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

3.  NHLBI workshop summary. Pulmonary complications of the acquired immunodeficiency syndrome: an update. Report of the second National Heart, Lung and Blood Institute workshop.

Authors:  J F Murray; S M Garay; P C Hopewell; J Mills; G L Snider; D E Stover
Journal:  Am Rev Respir Dis       Date:  1987-02

4.  Ultrasonic nebulised pentamidine for pneumocystis pneumonia.

Authors:  P M Girard; L J Couderc; R Farinotti; S Matheron; S Kernbaum; J P Coulaud; A G Saimot
Journal:  Lancet       Date:  1988-05-21       Impact factor: 79.321

5.  Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop.

Authors:  J F Murray; C P Felton; S M Garay; M S Gottlieb; P C Hopewell; D E Stover; A S Teirstein
Journal:  N Engl J Med       Date:  1984-06-21       Impact factor: 91.245

6.  Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

7.  Assessment of therapy for pneumocystis carinii pneumonia. PCP Therapy Project Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia.

Authors:  P M Girard; M Brun-Pascaud; R Farinotti; L Tamisier; S Kernbaum
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study.

Authors:  J E Conte; H Hollander; J A Golden
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

View more
  5 in total

Review 1.  Opportunistic protozoan infections in human immunodeficiency virus disease: review highlighting diagnostic and therapeutic aspects.

Authors:  A Curry; A J Turner; S Lucas
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

2.  Effect of terbutaline on bronchoconstriction induced by nebulised pentamidine.

Authors:  T R Leigh; J Wiggins; B G Gazzard; J V Collins
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

3.  Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.

Authors:  T J O'Leary; M M Tsai; C F Wright; M T Cushion
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

4.  High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

Authors:  R Zangerle; F Allerberger; P Pohl; P Fritsch; M P Dierich
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

Review 5.  Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients.

Authors:  D Smith; B Gazzard
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.